These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 15846528)
21. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Florin TH Med J Aust; 2004 Mar; 180(6):310-2; author reply 311-2. PubMed ID: 15012575 [No Abstract] [Full Text] [Related]
22. Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. Behan K; Cutts C; Tett SE Eur J Clin Pharmacol; 2005 Mar; 61(1):55-8. PubMed ID: 15785961 [TBL] [Abstract][Full Text] [Related]
25. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Hochberg MC Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939 [TBL] [Abstract][Full Text] [Related]
26. COX-2 inhibitors and cardiovascular toxicity: a class effect? Laible B S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479 [No Abstract] [Full Text] [Related]
27. COX-2 inhibitors--a lesson in unexpected problems. Drazen JM N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947 [No Abstract] [Full Text] [Related]
28. Blood pressure in Native Americans switched from celecoxib to rofecoxib. Fredy J; Diggins DA; Morrill GB Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981 [TBL] [Abstract][Full Text] [Related]
36. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
37. [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine]. Krüger K Z Rheumatol; 2001 Dec; 60(6):481-4. PubMed ID: 11826746 [No Abstract] [Full Text] [Related]
38. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. Spalding WM; Reeves MJ; Whelton A Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969 [TBL] [Abstract][Full Text] [Related]
39. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases. Gibofsky A J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424 [TBL] [Abstract][Full Text] [Related]
40. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]